Henry Kaminski, MD
Disclosures: Consultant-UCB Pharmaceuticals-FCRN inhibitor|Consultant-RA Pharmaceuticals-complement inhibitor|Consultant-Alnylam-complement inhibitor|Consultant-DAS Therapeutics-cholinesterase inhibitor|Holder of Intellectual Property Rights-ARC Biotechnology-complement inhibitor|Consultant-Cabelleta Bio-CAAR T Cell
No Bio Available.